checkAd

     123  0 Kommentare Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children’s Hospital Medical Center to Develop a Novel Treatment for Select CNS Disorders - Seite 3

    Company Contacts:
    Jaclyn Jaffe and William Begien
    Fortress Biotech, Inc.
    (781) 652-4500
    ir@fortressbiotech.com

    Investor Relations Contact:
    Daniel Ferry
    LifeSci Advisors, LLC
    (617) 430-7576
    daniel@lifesciadvisors.com

    Lesen Sie auch

    Media Relations Contact:
    Tony Plohoros
    6 Degrees
    (908) 591-2839
    tplohoros@6degreespr.com

    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children’s Hospital Medical Center to Develop a Novel Treatment for Select CNS Disorders - Seite 3 Baergic Bio, a Fortress partner company, enters into an agreement with AstraZeneca for AZD7325, a novel α2/3–subtype-selective GABA A positive allosteric modulatorNEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) - Fortress Biotech, Inc. (Nasdaq: FBIO) …